Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5305)
All Articles published online
|
Nov 28, 2006 (publication date) through Nov 27, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Jazii FR, Najafi Z, Malekzadeh R, Conrads TP, Ziaee AA, Abnet C, Yazdznbod M, Karkhane AA, Salekdeh GH. Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer. World J Gastroenterol 2006; 12(44): 7104-7112 [PMID: 17131471 DOI: 10.3748/wjg.v12.i44.7104] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v12/i44/7104.htm |
| Number | Citing Articles |
| 1 |
Enrique Grande, María-Victoria Bolós, Edurne Arriola. Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment. Molecular Cancer Therapeutics 2011; 10(4): 569 doi: 10.1158/1535-7163.MCT-10-0615
|
| 2 |
Yung-Jue Bang. The potential for crizotinib in non-small cell lung cancer: a perspective review. Therapeutic Advances in Medical Oncology 2011; 3(6): 279 doi: 10.1177/1758834011419002
|
| 3 |
Björn L. D. M. Brücher, Yan Li, Philipp Schnabel, Martin Daumer, Timothy J. Wallace, Rainer Kube, Bruno Zilberstein, Scott Steele, Jan L. A. Voskuil, Ijaz S. Jamall. Genomics, microRNA, epigenetics, and proteomics for future diagnosis, treatment and monitoring response in upper GI cancers. Clinical and Translational Medicine 2016; 5(1) doi: 10.1186/s40169-016-0093-6
|
| 4 |
Larisa V Debelenko, Susana C Raimondi, Najat Daw, Bangalore R Shivakumar, Dali Huang, Marilu Nelson, Julia A Bridge. Renal cell carcinoma with novel VCL–ALK fusion: new representative of ALK-associated tumor spectrum. Modern Pathology 2011; 24(3): 430 doi: 10.1038/modpathol.2010.213
|
| 5 |
Yi-Jun Qi, Wei-Xia Chao, Jen-Fu Chiu. An overview of esophageal squamous cell carcinoma proteomics. Journal of Proteomics 2012; 75(11): 3129 doi: 10.1016/j.jprot.2012.04.025
|
| 6 |
Ju Gao, Minzhi Yin, Yiping Zhu, Ling Gu, Yanle Zhang, Qiang Li, Cangsong Jia, Zhigui Ma. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma. BMC Cancer 2013; 13(1) doi: 10.1186/1471-2407-13-471
|
| 7 |
Diletta Fontana, Monica Ceccon, Carlo Gambacorti‐Passerini, Luca Mologni. Activity of second‐generation ALK inhibitors against crizotinib‐resistant mutants in an NPM‐ALK model compared to EML4‐ALK. Cancer Medicine 2015; 4(7): 953 doi: 10.1002/cam4.413
|
| 8 |
Pierre Tennstedt, Gundula Strobel, Charlotte Bölch, Tobias Grob, Sarah Minner, Sawinee Masser, Ronald Simon. Patterns of ALK expression in different human cancer types. Journal of Clinical Pathology 2014; 67(6): 477 doi: 10.1136/jclinpath-2013-201991
|
| 9 |
Kazutomo Kinoshita, Takamitsu Kobayashi, Kohsuke Asoh, Noriyuki Furuichi, Toshiya Ito, Hatsuo Kawada, Sousuke Hara, Jun Ohwada, Kazuo Hattori, Takuho Miyagi, Woo-Sang Hong, Min-Jeong Park, Kenji Takanashi, Toshiyuki Tsukaguchi, Hiroshi Sakamoto, Takuo Tsukuda, Nobuhiro Oikawa. 9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors. Journal of Medicinal Chemistry 2011; 54(18): 6286 doi: 10.1021/jm200652u
|
| 10 |
P Bavi, Z Jehan, R Bu, S Prabhakaran, N Al-Sanea, F Al-Dayel, M Al-Assiri, T Al-Halouly, R Sairafi, S Uddin, K S Al-Kuraya. ALK gene amplification is associated with poor prognosis in colorectal carcinoma. British Journal of Cancer 2013; 109(10): 2735 doi: 10.1038/bjc.2013.641
|
| 11 |
Zahra Najafi, Abdolreza Mohamadnia, Rahim Ahmadi, Minoo Mahmoodi, Naghmeh Bahrami, Adnan Khosravi, Hamid Reza Jamaati, Payam Tabarsi, Mehdi Kazempour Dizaji, Alireza Mosavi Jarrahi. The Identification of Cytochrome B5 Reductase 2 and Fructose-1,6-Bisphosphatase 1 Proteins in Non-Small Cell Lung Cancer: Proteomics Approach. International Journal of Cancer Management 2020; 13(12) doi: 10.5812/ijcm.101486
|
| 12 |
Ashraf A. Khalil, Nihal F. Kabapy, Sahar F. Deraz, Christopher Smith. Heat shock proteins in oncology: Diagnostic biomarkers or therapeutic targets?. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2011; 1816(2): 89 doi: 10.1016/j.bbcan.2011.05.001
|
| 13 |
Geeta Sharma, Ines Mota, Luca Mologni, Enrico Patrucco, Carlo Gambacorti-Passerini, Roberto Chiarle. Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes. Cancers 2018; 10(3): 62 doi: 10.3390/cancers10030062
|
| 14 |
K Hellman, A A Alaiya, S Becker, M Lomnytska, K Schedvins, W Steinberg, A-C Hellström, S Andersson, U Hellman, G Auer. Differential tissue-specific protein markers of vaginal carcinoma. British Journal of Cancer 2009; 100(8): 1303 doi: 10.1038/sj.bjc.6604975
|
| 15 |
S Röttgers, M Gombert, A Teigler-Schlegel, K Busch, U Gamerdinger, R Slany, J Harbott, A Borkhardt. ALK fusion genes in children with atypical myeloproliferative leukemia. Leukemia 2010; 24(6): 1197 doi: 10.1038/leu.2010.18
|
| 16 |
Jessica J. Lin, Gregory J. Riely, Alice T. Shaw. Targeting ALK: Precision Medicine Takes on Drug Resistance. Cancer Discovery 2017; 7(2): 137 doi: 10.1158/2159-8290.CD-16-1123
|
| 17 |
John A. Papalas, Evan Kulbacki, Endi Wang. Anaplastic Lymphoma Kinase (ALK1) Immunohistochemistry in Diagnostic Dermatopathology; An Update. The American Journal of Dermatopathology 2013; 35(4): 403 doi: 10.1097/DAD.0b013e31823d2943
|
| 18 |
Mehdi Moghanibashi, Ferdous Rastgar Jazii, Zahra-Soheila Soheili, Maryam Zare, Aliasghar Karkhane, Kazem Parivar, Parisa Mohamadynejad. Proteomics of a new esophageal cancer cell line established from Persian patient. Gene 2012; 500(1): 124 doi: 10.1016/j.gene.2012.03.038
|
| 19 |
Shenjie Li, Wei Xiang, Junjie Tian, Haorun Wang, Shuiwang Hu, Ke Wang, Ligang Chen, Changren Huang, Jie Zhou, Somchai Chutipongtanate. Bone Marrow-Derived Mesenchymal Stem Cells Differentially Affect Glioblastoma Cell Proliferation, Migration, and Invasion: A 2D-DIGE Proteomic Analysis. BioMed Research International 2021; 2021: 1 doi: 10.1155/2021/4952876
|
| 20 |
Rongshi Li, Stephan W. Morris. Development of anaplastic lymphoma kinase (ALK) small‐molecule inhibitors for cancer therapy. Medicinal Research Reviews 2008; 28(3): 372 doi: 10.1002/med.20109
|
| 21 |
Luca Mologni. Therapeutic Strategies to Overcome ALK Resistance in Cancer. 2021; : 101 doi: 10.1016/B978-0-12-821774-0.00005-X
|
| 22 |
Meng-Tian Li, Jun-Yun Liang, Yi-Ping Sun, Jian Jin, Yue Xiong, Kun-Liang Guan, Hai-Xin Yuan. ELP3 Acetyltransferase is phosphorylated and regulated by the oncogenic anaplastic lymphoma kinase (ALK). Biochemical Journal 2019; 476(15): 2239 doi: 10.1042/BCJ20190106
|
| 23 |
Jeong In Yun, Eun Hye Yang, Muhammad Latif, Hyeon Ji Lee, Kwangho Lee, Chang-Soo Yun, Chi Hoon Park, Chong Ock Lee, Chong Hak Chae, Sung Yun Cho, Hee Jung Jung, Pilho Kim, Sang Un Choi, Hyoung Rae Kim. Novel 2,4-dianilino-5-fluoropyrimidine derivatives possessing ALK inhibitory activities. Archives of Pharmacal Research 2014; 37(7): 873 doi: 10.1007/s12272-013-0247-7
|
| 24 |
L Gu, J Gao, Q Li, Y P Zhu, C S Jia, R Y Fu, Y Chen, Q K Liao, Z Ma. Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis. Leukemia 2008; 22(11): 2091 doi: 10.1038/leu.2008.204
|
| 25 |
Luca Mologni, Carlo Gambacorti-Passerini. New developments in the treatment of ALK-driven malignancies. Clinical Investigation 2012; 2(8): 835 doi: 10.4155/cli.12.67
|
| 26 |
Rebecca J. Deyell, Edward F. Attiyeh. Advances in the understanding of constitutional and somatic genomic alterations in neuroblastoma. Cancer Genetics 2011; 204(3): 113 doi: 10.1016/j.cancergen.2011.03.001
|
| 27 |
E L Carpenter, E A Haglund, E M Mace, D Deng, D Martinez, A C Wood, A K Chow, D A Weiser, L T Belcastro, C Winter, S C Bresler, S Asgharzadeh, R C Seeger, H Zhao, R Guo, J G Christensen, J S Orange, B R Pawel, M A Lemmon, Y P Mossé. Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma. Oncogene 2012; 31(46): 4859 doi: 10.1038/onc.2011.647
|
| 28 |
M.D. Pastor, A. Nogal, S. Molina-Pinelo, R. Meléndez, A. Salinas, M. González De la Peña, J. Martín-Juan, J. Corral, R. García-Carbonero, A. Carnero, L. Paz-Ares. Identification of proteomic signatures associated with lung cancer and COPD. Journal of Proteomics 2013; 89: 227 doi: 10.1016/j.jprot.2013.04.037
|
| 29 |
E. Ardini, P. Magnaghi, P. Orsini, A. Galvani, M. Menichincheri. Anaplastic Lymphoma Kinase: Role in specific tumours, and development of small molecule inhibitors for cancer therapy. Cancer Letters 2010; 299(2): 81 doi: 10.1016/j.canlet.2010.09.001
|
| 30 |
John M. Hatcher, Magda Bahcall, Hwan Geun Choi, Yang Gao, Taebo Sim, Rani George, Pasi A. Jänne, Nathanael S. Gray. Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. Journal of Medicinal Chemistry 2015; 58(23): 9296 doi: 10.1021/acs.jmedchem.5b01136
|
| 31 |
Vanessa P Tolbert, Grace E Coggins, John M Maris. Genetic susceptibility to neuroblastoma. Current Opinion in Genetics & Development 2017; 42: 81 doi: 10.1016/j.gde.2017.03.008
|
| 32 |
Yaqing Zhang, Jie Sun, Yongxi Song, Peng Gao, Xin Wang, Miao Chen, Yuan Li, Zhonghua Wu. Roles of fusion genes in digestive system cancers: Dawn for cancer precision therapy. Critical Reviews in Oncology/Hematology 2022; 171: 103622 doi: 10.1016/j.critrevonc.2022.103622
|
| 33 |
Ji-Hun Lim, Seongsoo Jang, Chan-Jeoung Park, Young-Uk Cho, Je-Hwan Lee, Kyoo-Hyung Lee, Jin-Ok Lee, Jong-Yeon Shin, Jong-Il Kim, Jooryung Huh, Eul-Ju Seo. RANBP2-ALK fusion combined with monosomy 7 in acute myelomonocytic leukemia. Cancer Genetics 2014; 207(1-2): 40 doi: 10.1016/j.cancergen.2013.12.003
|
| 34 |
Gordana Raca, Jo-Anne van der Krogt, Michelle M. Le Beau, Iwona Wlodarska. Rare Lymphomas. 2014; : 17 doi: 10.1007/978-3-642-39590-1_2
|
| 35 |
Paul Scott Thorner, Mary Shago, Paula Marrano, Furqan Shaikh, Gino R. Somers. TFE3-positive renal cell carcinomas are not always Xp11 translocation carcinomas: Report of a case with a TPM3-ALK translocation. Pathology - Research and Practice 2016; 212(10): 937 doi: 10.1016/j.prp.2016.07.004
|
| 36 |
Luca Mologni. Inhibitors of the anaplastic lymphoma kinase. Expert Opinion on Investigational Drugs 2012; 21(7): 985 doi: 10.1517/13543784.2012.690031
|
| 37 |
Abhilash Perisetti, Mahita Bellamkonda, Manojna Konda, Samantha Edwards, Salman Ali Khan, Pardeep Bansal, Zhi-De Hu, Hemant Goyal. Tumor-associated antigens and their antibodies in the screening, diagnosis, and monitoring of esophageal cancers. European Journal of Gastroenterology & Hepatology 2020; 32(7): 779 doi: 10.1097/MEG.0000000000001718
|
| 38 |
Vandana Batra, Rebecca J. Deyell, John M. Maris. Molecular Oncology. 2013; : 669 doi: 10.1017/CBO9781139046947.060
|
| 39 |
Yan‐Xin Luo, Ji Cui, Lei Wang, Dian‐Ke Chen, Jun‐Sheng Peng, Ping Lan, Mei‐Jin Huang, Yi‐Hua Huang, Shi‐Rong Cai, Kun‐Hua Hu, Ming‐Tao Li, Jian‐Ping Wang. Identification of cancer‐associated proteins by proteomics and downregulation of β‐tropomyosin expression in colorectal adenoma and cancer. PROTEOMICS – Clinical Applications 2009; 3(12): 1397 doi: 10.1002/prca.200900070
|
| 40 |
Eri Kubo, Nailia Hasanova, Hiroshi Sasaki, Dhirendra P. Singh. Dynamic and differential regulation in the microRNA expression in the developing and mature cataractous rat lens. Journal of Cellular and Molecular Medicine 2013; 17(9): 1146 doi: 10.1111/jcmm.12094
|
| 41 |
C. George Priya Doss, Chiranjib Chakraborty, Luonan Chen, Hailong Zhu. IntegratingIn SilicoPrediction Methods, Molecular Docking, and Molecular Dynamics Simulation to Predict the Impact of ALK Missense Mutations in Structural Perspective. BioMed Research International 2014; 2014: 1 doi: 10.1155/2014/895831
|
| 42 |
|
| 43 |
J. Devon Roll, Gary W. Reuther, Antimo Migliaccio. ALK-Activating Homologous Mutations in LTK Induce Cellular Transformation. PLoS ONE 2012; 7(2): e31733 doi: 10.1371/journal.pone.0031733
|
| 44 |
Manoj Kumar Kashyap, Omar Abdel-Rahman. Expression, regulation and targeting of receptor tyrosine kinases in esophageal squamous cell carcinoma. Molecular Cancer 2018; 17(1) doi: 10.1186/s12943-018-0790-4
|
| 45 |
Roberto Chiarle, Claudia Voena, Chiara Ambrogio, Roberto Piva, Giorgio Inghirami. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nature Reviews Cancer 2008; 8(1): 11 doi: 10.1038/nrc2291
|
| 46 |
Chaitanya Iragavarapu, Milaim Mustafa, Akintunde Akinleye, Muhammad Furqan, Varun Mittal, Shundong Cang, Delong Liu. Novel ALK inhibitors in clinical use and development. Journal of Hematology & Oncology 2015; 8(1) doi: 10.1186/s13045-015-0122-8
|
| 47 |
Adrian Mariño-Enríquez, Paola Dal Cin. ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages. Cancer Genetics 2013; 206(11): 357 doi: 10.1016/j.cancergen.2013.07.001
|
| 48 |
Patrizia Bottoni, Bruno Giardina, Alessandro Pontoglio, Salvatore Scarà, Roberto Scatena. Advances in Mitochondrial Medicine. Advances in Experimental Medicine and Biology 2012; 942: 423 doi: 10.1007/978-94-007-2869-1_19
|
| 49 |
Seishi Ogawa, Junko Takita, Masashi Sanada, Yasuhide Hayashi. Oncogenic mutations of ALK in neuroblastoma. Cancer Science 2011; 102(2): 302 doi: 10.1111/j.1349-7006.2010.01825.x
|
| 50 |
Parisa Karimi, Armin Shahrokni, Mohammad R. Nezami Ranjbar. Implementation of Proteomics for Cancer Research: Past, Present, and Future. Asian Pacific Journal of Cancer Prevention 2014; 15(6): 2433 doi: 10.7314/APJCP.2014.15.6.2433
|
| 51 |
Chikako Fukushima, Akihiro Murakami, Keiko Yoshitomi, Kotaro Sueoka, Shugo Nawata, Kazuyuki Nakamura, Norihiro Sugino. Comparative proteomic profiling in squamous cell carcinoma of the uterine cervix. PROTEOMICS – Clinical Applications 2011; 5(3-4): 133 doi: 10.1002/prca.201000077
|
| 52 |
Ji Cui, Yonghua Cai, Ying Hu, Zenghong Huang, Yanxin Luo, Andrew M. Kaz, Zihuan Yang, Dianke Chen, Xinjuan Fan, William M. Grady, Jianping Wang. Epigenetic silencing of TPM2 contributes to colorectal cancer progression upon RhoA activation. Tumor Biology 2016; 37(9): 12477 doi: 10.1007/s13277-016-5103-1
|
| 53 |
Rui Yang, Gang Zheng, Defa Ren, Chunzhou Chen, Cheng Zeng, Wei Lu, Hua Li. The clinical significance and biological function of tropomyosin 4 in colon cancer. Biomedicine & Pharmacotherapy 2018; 101: 1 doi: 10.1016/j.biopha.2018.01.166
|
| 54 |
Daisuke Takagi, Yasutoshi Tatsumi, Tomoki Yokochi, Atsushi Takatori, Miki Ohira, Takehiko Kamijo, Satoshi Kondo, Yoshitaka Fujii, Akira Nakagawara. Novel adaptor protein Shf interacts with ALK receptor and negatively regulates its downstream signals in neuroblastoma. Cancer Science 2013; 104(5): 563 doi: 10.1111/cas.12115
|
| 55 |
Kengo Takeuchi, Manabu Soda, Yuki Togashi, Emiko Sugawara, Satoko Hatano, Reimi Asaka, Sakae Okumura, Ken Nakagawa, Hiroyuki Mano, Yuichi Ishikawa. Pulmonary Inflammatory Myofibroblastic Tumor Expressing a Novel Fusion, PPFIBP1–ALK: Reappraisal of Anti-ALK Immunohistochemistry as a Tool for Novel ALK Fusion Identification. Clinical Cancer Research 2011; 17(10): 3341 doi: 10.1158/1078-0432.CCR-11-0063
|
| 56 |
Harsh Pawar, Manoj Kumar Kashyap, Nandini A. Sahasrabuddhe, Santosh Renuse, H. C. Harsha, Praveen Kumar, Jyoti Sharma, Kumaran Kandasamy, Arivusudar Marimuthu, Bipin Nair, Sudha Rajagopalan, Jagadeesha Maharudraiah, Chennagiri Shrinivasamurthy Premalatha, Kariyanakatte Veeraiah Veerendra Kumar, M. Vijayakumar, Raghothama Chaerkady, Thotterthodi Subrahmanya Keshava Prasad, Rekha V. Kumar, Akhilesh Pandey. Quantitative tissue proteomics of esophageal squamous cell carcinoma for novel biomarker discovery. Cancer Biology & Therapy 2011; 12(6): 510 doi: 10.4161/cbt.12.6.16833
|
| 57 |
Franck Brouillard, Janine Fritsch, Aleksander Edelman, Mario Ollero. Contribution of proteomics to the study of the role of cytokeratins in disease and physiopathology. PROTEOMICS – Clinical Applications 2008; 2(2): 264 doi: 10.1002/prca.200780018
|
| 58 |
Jianyong Chen, Yunlong Zhou, Xuyuan Dong, Liu Liu, Longchuan Bai, Donna McEachern, Sally Przybranowski, Chao-Yie Yang, Jeanne Stuckey, Xiaoqin Li, Bo Wen, Ting Zhao, Siwei Sun, Duxin Sun, Lingling Jiao, Yu Jing, Ming Guo, Dajun Yang, Shaomeng Wang. Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression. Journal of Medicinal Chemistry 2020; 63(22): 13994 doi: 10.1021/acs.jmedchem.0c01550
|
| 59 |
Ruth H. Palmer, Bengt Hallberg. Receptor Tyrosine Kinases: Family and Subfamilies. 2015; : 1 doi: 10.1007/978-3-319-11888-8_1
|
| 60 |
Saemina Shin, Shinmee Mah, Sungwoo Hong, Hwangseo Park. Discovery of Low Micromolar Dual Inhibitors for Wild Type and L1196M Mutant of Anaplastic Lymphoma Kinase through Structure-Based Virtual Screening. Journal of Chemical Information and Modeling 2016; 56(4): 802 doi: 10.1021/acs.jcim.6b00026
|
| 61 |
Arata Tomiyama, Takamasa Uekita, Reiko Kamata, Kazuki Sasaki, Junko Takita, Miki Ohira, Akira Nakagawara, Chifumi Kitanaka, Kentaro Mori, Hideki Yamaguchi, Ryuichi Sakai. Flotillin-1 Regulates Oncogenic Signaling in Neuroblastoma Cells by Regulating ALK Membrane Association. Cancer Research 2014; 74(14): 3790 doi: 10.1158/0008-5472.CAN-14-0241
|
| 62 |
Hanna Ning, Hiroshi Mitsui, Claire Q.F. Wang, Mayte Suárez-Fariñas, Juana Gonzalez, Kejal R. Shah, Jie Chen, Israel Coats, Diane Felsen, John A. Carucci, James G. Krueger. Identification of anaplastic lymphoma kinase as a potential therapeutic target in Basal Cell Carcinoma. Oncotarget 2013; 4(12): 2237 doi: 10.18632/oncotarget.1357
|
| 63 |
Alice T. Shaw, Peggy P. Hsu, Mark M. Awad, Jeffrey A. Engelman. Tyrosine kinase gene rearrangements in epithelial malignancies. Nature Reviews Cancer 2013; 13(11): 772 doi: 10.1038/nrc3612
|
| 64 |
Hiroyuki Mano. ALKoma: A Cancer Subtype with a Shared Target. Cancer Discovery 2012; 2(6): 495 doi: 10.1158/2159-8290.CD-12-0009
|
| 65 |
O. S. Kolovskaya, T. N. Zamay, A. S. Zamay, Y. E. Glazyrin, E. A. Spivak, O. A. Zubkova, A. V. Kadkina, E. N. Erkaev, G. S. Zamay, A. G. Savitskaya, L. V. Trufanova, L. L. Petrova, M. V. Berezovski. DNA-aptamer/protein interaction as a cause of apoptosis and arrest of proliferation in Ehrlich ascites adenocarcinoma cells. Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology 2014; 8(1): 60 doi: 10.1134/S1990747813050061
|
| 66 |
Yong-Fu Qiu, Lian-Hua Song, Gang-Long Jiang, Zhen Zhang, Xu-Yan Liu, Guan Wang. Hallmarks of Anaplastic Lymphoma Kinase Inhibitors with Its Quick Emergence of Drug Resistance. Pharmaceutical Fronts 2022; 4(04): e223 doi: 10.1055/s-0042-1758542
|
| 67 |
Yuki Togashi, Manabu Soda, Seiji Sakata, Emiko Sugawara, Satoko Hatano, Reimi Asaka, Takashi Nakajima, Hiroyuki Mano, Kengo Takeuchi, Anthony W.I. Lo. KLC1-ALK: A Novel Fusion in Lung Cancer Identified Using a Formalin-Fixed Paraffin-Embedded Tissue Only. PLoS ONE 2012; 7(2): e31323 doi: 10.1371/journal.pone.0031323
|
| 68 |
Shobha Dagamajalu, Manavalan Vijayakumar, Rohan Shetty, D. A. B. Rex, Chinmaya Narayana Kotimoole, T. S. Keshava Prasad. Proteogenomic examination of esophageal squamous cell carcinoma (ESCC): new lines of inquiry. Expert Review of Proteomics 2020; 17(9): 649 doi: 10.1080/14789450.2020.1845146
|
| 69 |
Linda F. Epstein, Hao Chen, Renee Emkey, Douglas A. Whittington. The R1275Q Neuroblastoma Mutant and Certain ATP-competitive Inhibitors Stabilize Alternative Activation Loop Conformations of Anaplastic Lymphoma Kinase. Journal of Biological Chemistry 2012; 287(44): 37447 doi: 10.1074/jbc.M112.391425
|
| 70 |
Shahid G. Farid, Gareth Morris-Stiff. “OMICS” technologies and their role in foregut primary malignancies. Current Problems in Surgery 2015; 52(10): 409 doi: 10.1067/j.cpsurg.2015.08.001
|
| 71 |
Jianming Ying, Chen Lin, Jian Wu, Lei Guo, Tian Qiu, Yun Ling, Ling Shan, Haitao Zhou, Dongbing Zhao, Jian Wang, Jianwei Liang, Jianjun Zhao, Yuchen Jiao, Ning Lu, Hong Zhao, Chandan Kumar-Sinha. Anaplastic Lymphoma Kinase Rearrangement in Digestive Tract Cancer: Implication for Targeted Therapy in Chinese Population. PLOS ONE 2015; 10(12): e0144731 doi: 10.1371/journal.pone.0144731
|
| 72 |
Benjamin Solomon, Marileila Varella-Garcia, D Ross Camidge. ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2009; 4(12): 1450 doi: 10.1097/JTO.0b013e3181c4dedb
|
| 73 |
Steve A Maxwell, Seyed Mousavi-Fard. Non-Hodgkin’s B-cell lymphoma: Advances in molecular strategies targeting drug resistance. Experimental Biology and Medicine 2013; 238(9): 971 doi: 10.1177/1535370213498985
|
| 74 |
J Okubo, J Takita, Y Chen, K Oki, R Nishimura, M Kato, M Sanada, M Hiwatari, Y Hayashi, T Igarashi, S Ogawa. Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma. Oncogene 2012; 31(44): 4667 doi: 10.1038/onc.2011.616
|
| 75 |
Yaël P. Mossé, Marci Laudenslager, Luca Longo, Kristina A. Cole, Andrew Wood, Edward F. Attiyeh, Michael J. Laquaglia, Rachel Sennett, Jill E. Lynch, Patrizia Perri, Geneviève Laureys, Frank Speleman, Cecilia Kim, Cuiping Hou, Hakon Hakonarson, Ali Torkamani, Nicholas J. Schork, Garrett M. Brodeur, Gian P. Tonini, Eric Rappaport, Marcella Devoto, John M. Maris. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008; 455(7215): 930 doi: 10.1038/nature07261
|
| 76 |
John F. Lechner, Rashmeet K. Reen, Alan A. Dombkowski, Daniela Cukovic, Sridevi Salagrama, Li-Shu Wang, Gary D. Stoner. Effects of a Black Raspberry Diet on Gene Expression in the Rat Esophagus. Nutrition and Cancer 2008; 60(sup1): 61 doi: 10.1080/01635580802393118
|
| 77 |
Joel D. Pearson, Jason K. H. Lee, Julinor T. C. Bacani, Raymond Lai, Robert J. Ingham. NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases. Journal of Signal Transduction 2012; 2012: 1 doi: 10.1155/2012/123253
|
| 78 |
Muhammad Latif, Zaman Ashraf, Sulman Basit, Abdul Ghaffar, Muhammad Sohail Zafar, Aamer Saeed, Sultan Ayoub Meo. Latest perspectives of orally bioavailable 2,4-diarylaminopyrimidine analogues (DAAPalogues) as anaplastic lymphoma kinase inhibitors: discovery and clinical developments. RSC Advances 2018; 8(30): 16470 doi: 10.1039/C8RA01934G
|
| 79 |
Robert Roskoski. Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition. Pharmacological Research 2013; 68(1): 68 doi: 10.1016/j.phrs.2012.11.007
|
| 80 |
Sebastian F. Schoppmann, Berthold Streubel, Peter Birner. Amplification but not translocation of anaplastic lymphoma kinase is a frequent event in oesophageal cancer. European Journal of Cancer 2013; 49(8): 1876 doi: 10.1016/j.ejca.2013.02.005
|
| 81 |
Yoshihisa Fujita, Toyofumi Nakanishi, Yoshiharu Miyamoto, Masako Hiramatsu, Hideaki Mabuchi, Akiko Miyamoto, Akira Shimizu, Takayuki Takubo, Nobuhiko Tanigawa. Proteomics-based identification of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinoma. Cancer Letters 2008; 263(2): 280 doi: 10.1016/j.canlet.2008.01.013
|
| 82 |
Jianyong Chen, Cheng Jiang, Shaomeng Wang. LDK378: A Promising Anaplastic Lymphoma Kinase (ALK) Inhibitor. Journal of Medicinal Chemistry 2013; 56(14): 5673 doi: 10.1021/jm401005u
|
| 83 |
Maryam Alizadeh, Leila Yousefi, Farzaneh Pakdel, Reza Ghotaslou, Mohammad Ahangarzadeh Rezaee, Ehsaneh Khodadadi, Mahin Ahangar Oskouei, Mohammad Hossein Soroush Barhaghi, Hossein Samadi Kafil, Mahmoud S. Ahmed. MALDI-TOF Mass Spectroscopy Applications in Clinical Microbiology. Advances in Pharmacological and Pharmaceutical Sciences 2021; 2021: 1 doi: 10.1155/2021/9928238
|
| 84 |
Yael P. Mossé, Andrew Wood, John M. Maris. Inhibition of ALK Signaling for Cancer Therapy. Clinical Cancer Research 2009; 15(18): 5609 doi: 10.1158/1078-0432.CCR-08-2762
|
| 85 |
Shahla Mohammad Ganji, Abbas Sahebghadam-Lotfi, Ferdous Rastgar-Jazii, Mansour Yazdanbod, Ali Mota, Afshin Mohsenifar, Anooshirvan Kazemnejad. Alpha-1 Antitrypsin Deficient Squamous Cell Carcinoma of Esophagus in the Azeri Population of Iran. Laboratory Medicine 2010; 41(10): 613 doi: 10.1309/LMA5KT05RBQKNFQJ
|
| 86 |
Bengt Hallberg, Ruth H. Palmer. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nature Reviews Cancer 2013; 13(10): 685 doi: 10.1038/nrc3580
|
| 87 |
Gerd Jomrich, Dagmar Kollmann, Winny Yan, Daniel Winkler, Matthias Paireder, Lisa Gensthaler, Hannah Christina Puhr, Aysegül Ilhan-Mutlu, Reza Asari, Sebastian F. Schoppmann. Overexpression of Fibroblast Growth Factor 8 Is a Predictor of Impaired Survival in Esophageal Squamous Cell Carcinoma and Correlates with ALK/EML4 Alteration. Cancers 2024; 16(21): 3624 doi: 10.3390/cancers16213624
|
| 88 |
Mahin Gholipour, Farhad Islami, Gholamreza Roshandel, Masoud Khoshnia, Abbas Badakhshan, Abdolvahab Moradi, Reza Malekzadeh. Esophageal Cancer in Golestan Province, Iran: A Review of Genetic Susceptibility and Environmental Risk Factors. Middle East Journal of Digestive Diseases 2016; 8(4): 249 doi: 10.15171/mejdd.2016.34
|
| 89 |
Kai Ou, Xiu Liu, Weihua Li, Yi Yang, Jianming Ying, Lin Yang. ALK Rearrangement–Positive Pancreatic Cancer with Brain Metastasis Has Remarkable Response to ALK Inhibitors: A Case Report. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.724815
|
| 90 |
Antonella Barreca, Elena Lasorsa, Ludovica Riera, Rodolfo Machiorlatti, Roberto Piva, Maurilio Ponzoni, Ivo Kwee, Francesco Bertoni, Pier Paolo Piccaluga, Stefano A Pileri, Giorgio Inghirami, _ _. Anaplastic lymphoma kinase in human cancer. Journal of Molecular Endocrinology 2011; 47(1): R11 doi: 10.1530/JME-11-0004
|
| 91 |
Sarah Boyle, Zlatko Kopecki. Squamous Cell Carcinoma - Hallmark and Treatment Modalities. 2020; doi: 10.5772/intechopen.86041
|
| 92 |
Hitoyasu Futami, Ryuichi Sakai. All-trans retinoic acid downregulates ALK in neuroblastoma cell lines and induces apoptosis in neuroblastoma cell lines with activated ALK. Cancer Letters 2010; 297(2): 220 doi: 10.1016/j.canlet.2010.05.014
|
| 93 |
Fiona Kate Elizabeth McDuff, Suzanne Dawn Turner, Alfons Navarro. Aberrant Anaplastic Lymphoma Kinase Activity Induces a p53 and Rb-Dependent Senescence-Like Arrest in the Absence of Detectable p53 Stabilization. PLoS ONE 2011; 6(3): e17854 doi: 10.1371/journal.pone.0017854
|
| 94 |
Wolfgang J. Köstler, Christoph C. Zielinski. Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease. 2015; : 225 doi: 10.1007/978-1-4939-2053-2_10
|
| 95 |
Patrizia Bottoni, Bruno Giardina, Roberto Scatena. Proteomic profiling of heat shock proteins: An emerging molecular approach with direct pathophysiological and clinical implications. PROTEOMICS – Clinical Applications 2009; 3(6): 636 doi: 10.1002/prca.200800195
|
| 96 |
Ruth H. Palmer, Emma Vernersson, Caroline Grabbe, Bengt Hallberg. Anaplastic lymphoma kinase: signalling in development and disease. Biochemical Journal 2009; 420(3): 345 doi: 10.1042/BJ20090387
|
| 97 |
Gang Wu, Raymond L Barnhill, Seungjae Lee, Yongjin Li, Ying Shao, John Easton, James Dalton, Jinghui Zhang, Alberto Pappo, Armita Bahrami. The landscape of fusion transcripts in spitzoid melanoma and biologically indeterminate spitzoid tumors by RNA sequencing. Modern Pathology 2016; 29(4): 359 doi: 10.1038/modpathol.2016.37
|
| 98 |
|
| 99 |
Zhifa Cao, Qian Gao, Meixian Fu, Nan Ni, Yuting Pei, Wen‑Bin Ou. Anaplastic lymphoma kinase fusions: Roles in cancer and therapeutic perspectives (Review). Oncology Letters 2018; doi: 10.3892/ol.2018.9856
|
| 100 |
Thomas R Webb, Jake Slavish, Rani E George, A Thomas Look, Liquan Xue, Qin Jiang, Xiaoli Cui, Walter B Rentrop, Stephan W Morris. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Review of Anticancer Therapy 2009; 9(3): 331 doi: 10.1586/14737140.9.3.331
|
| 101 |
Hideko Isozaki, Nagio Takigawa, Katsuyuki Kiura. Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer. Cancers 2015; 7(2): 763 doi: 10.3390/cancers7020763
|
| 102 |
Chris W. Sutton, Nitin Rustogi, Cemal Gurkan, Andrew Scally, Maria A. Loizidou, Andreas Hadjisavvas, Kyriacos Kyriacou. Quantitative Proteomic Profiling of Matched Normal and Tumor Breast Tissues. Journal of Proteome Research 2010; 9(8): 3891 doi: 10.1021/pr100113a
|
| 103 |
Lan Wang, Vivian Wai Yan Lui. Emerging Roles of ALK in Immunity and Insights for Immunotherapy. Cancers 2020; 12(2): 426 doi: 10.3390/cancers12020426
|
| 104 |
Fergal C. Kelleher, Ray McDermott. The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene. European Journal of Cancer 2010; 46(13): 2357 doi: 10.1016/j.ejca.2010.04.006
|
| 105 |
Maryam Zare, Ferdous Rastgar Jazii, Zahra‐Soheila Soheili, Mohamad‐Mehdi Moghanibashi. Downregulation of tropomyosin‐1 in squamous cell carcinoma of esophagus, the role of Ras signaling and methylation. Molecular Carcinogenesis 2012; 51(10): 796 doi: 10.1002/mc.20847
|
| 106 |
Adam Gorczyński, Monika Prełowska, Patrick Adam, Piotr Czapiewski, Wojciech Biernat. ALK-Positive Cancer: Still a Growing Entity. Future Oncology 2014; 10(2): 305 doi: 10.2217/fon.13.184
|
| 107 |
Tommaso De Pas, Laura Pala, Chiara Catania, Fabio Conforti. Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib. Future Oncology 2017; 13(29): 2629 doi: 10.2217/fon-2017-0262
|
| 108 |
Shinmee Mah, Jaebong Jang, Daesun Song, Yongje Shin, Muhammad Latif, Yongwon Jung, Sungwoo Hong. Discovery of fluorescent 3-heteroarylcoumarin derivatives as novel inhibitors of anaplastic lymphoma kinase. Organic & Biomolecular Chemistry 2019; 17(1): 186 doi: 10.1039/C8OB02874E
|
| 109 |
Mario Capasso, Sharon J. Diskin. Cancer Genetics. Cancer Treatment and Research 2010; 155: 65 doi: 10.1007/978-1-4419-6033-7_4
|